Business
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept data from
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept data from ongoing Phase 1/2 trial in Thyroid Eye Disease selected for late-breaking presentation - - Mechanistic characterization of VRDN-001, a potential best-in-class full antagonist of IGF-1R, selected for oral highlighted late-breaking presentation - WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that three abstracts highlighting the potential benefits of VRDN-001 will be presented as oral highlighted and late-breaking poster presentations at the 91st Annual Meeting of the American Thyroid Association (ATA), to be held in Montreal, Canada from October 19 to 23, 2022. “We’re excited to share mechanistic and clinical data at this year’s ATA annual meeting that contribute to the emerging body of evidence demonstrating differentiation of VRDN-001 from current therapies,\" stated Jonathan Violin, Ph.D., Viridian Therapeutics’ President and CEO. “We are thrilled that the 10 mg/kg data from our Phase 1/2 trial was selected for a late-breaking presentation, and we look forward to presenting additional updates for both VRDN-001 and VRDN-002 later this quarter. These updates will include top-line data for the 20 mg/kg cohort of our ongoing Phase 1/2 trial of VRDN-001 in Thyroid Eye Disease, followed later this quarter by top-line data from the currently enrolling 3mg/kg cohort. This quarter we’ll also share additional pharmacokinetic and pharmacodynamic results from our first-in-human trial of VRDN-002, our half-life extended IGF-1R antibody, which reinforce and build upon the recently presented interim results.” Oral Highlighted Poster Session Details: Title:VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor Receptor-1 (IGF-1R) in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from TeprotumumabPoster:#132Session:#4 - Non-Thyroid Cancer Highlighted PostersTime and Date:Thursday, October 20, 2022, 4:00 p.m. to 4:30 p.m. ETRoom:511-CF Late-Breaking Poster Session Details: Title:VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor Receptor-1 (IGF-1...